Data / Form D filings / MalarVx, Inc.
MalarVx, Inc.: Form D filings
MalarVx, Inc., a biotechnology company in Seattle, WA, filed 6 Form D notices with the SEC between 2012 and 2026. The latest, on August 25, 2026, reports $125,000 sold of a $2.5 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1551 EASTLAKE AVE E SUITE 100, Seattle, WA, 98102
- Phone
- (646) 522-2458
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Washington
- Revenue range
- $1,000,001 - $5,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1559688
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | New notice | $2,500,000 | $125,000 | $2,375,000 | 2 | Aug 8, 2026 | sec.gov |
| Jun 21, 2017 | Amendment | $1,500,000 | $1,050,000 | $450,000 | 21 | Jan 2, 2015 | sec.gov |
| Nov 23, 2015 | New notice | $1,000,000 | $0 | $1,000,000 | 0 | Yet to occur | sec.gov |
| Jan 30, 2015 | Amendment | $900,000 | $110,000 | $790,000 | 4 | Jan 2, 2015 | sec.gov |
| Jan 20, 2015 | New notice | $900,000 | $110,000 | $790,000 | 4 | Jan 2, 2015 | sec.gov |
| Oct 18, 2012 | New notice | $250,000 | $0 | $250,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James n/a Davie | Director | |
| Jodi n/a Herczeg | Executive Officer |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
- Automera US Inc. $1 million · Aug 7, 2026
Every Form D from the week of Aug 24, 2026 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what MalarVx, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.